American biotech firm that uses gene-editing to treat ultra-rare genetic disorders. Launched in early 2026 by Jennifer Doudna, Nobel-prizewinning pioneer of CRISPR gene-editing.
If at first you don't succeed, destroy all evidence that you tried. -- Unknown